Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics Inc
(NQ:
MYGN
)
28.12
+0.46 (+1.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Myriad Genetics Inc
< Previous
1
2
3
4
Next >
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
August 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
August 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
July 31, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
July 17, 2024
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
July 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Earns 2024 Great Place To Work® Certification™
July 02, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
June 24, 2024
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Via
MarketBeat
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
June 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
May 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
Management will also participate in four upcoming investor healthcare conferences
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024
80% of people diagnosed with anxiety, depression report losing years or decades of time
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
April 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 21, 2024
Management will also participate in two upcoming healthcare conferences
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
February 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.